Study shows sharp reduction in market exclusivity periods for first-in-class treatment entrants.
Tufts, CSDD
Advertisement
Articles by Tufts, CSDD
Study finds that almost 75% of cancer drug candidates rely on biomarker data.
Advertisement
Latest Updated Articles
Between 2004 and 2012, the Number of Endpoints per Protocol has Nearly DoubledPublished: February 1st 2013 | Updated:
Survey Results of Start-Up Cycle TimesPublished: November 1st 2012 | Updated:
Oncology Leads Personalized MedicinePublished: June 1st 2015 | Updated:
Competitive Pressure for First-in-Class Drugs is IntensifyingPublished: February 1st 2016 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
